Suppr超能文献

硝苯地平或维拉帕米作为高血压的单一治疗方法。一项动脉内研究。

Nifedipine or verapamil as sole treatment of hypertension. An intraarterial study.

作者信息

Gould B A, Hornung R S, Mann S, Subramanian V B, Raftery E B

出版信息

Hypertension. 1983 Jul-Aug;5(4 Pt 2):II91-6. doi: 10.1161/01.hyp.5.4_pt_2.ii91.

Abstract

Intraarterial ambulatory blood pressures were recorded prior to and during therapy with two different calcium ion antagonists, nifedipine and verapamil, in two separate groups of patients. In the first group, nine patients were studied off therapy and following a minimum of 6 weeks of nifedipine treatment (dose range, 20 to 60 mg twice daily). A second group of 16 patients followed the identical protocol but were prescribed verapamil (120 to 160 mg, three times daily). During both studies, patients underwent standardized physiological tests including tilt, isometric handgrip, and dynamic bicycle exercise. Both verapamil and nifedipine caused a reduction in blood pressure over most of the 24 hours studied. Nifedipine did not affect heart rate whereas verapamil caused a reduction of approximately 10 bpm. Nifedipine and verapamil did not induce postural hypotension, and the absolute responses to dynamic and isometric exercise were reduced. These results show the efficacy of slow channel inhibitors in the management of essential hypertension.

摘要

在两组不同的患者中,分别记录了使用两种不同钙离子拮抗剂硝苯地平和维拉帕米治疗前及治疗期间的动脉动态血压。第一组,对9例患者在未治疗时以及至少6周的硝苯地平治疗后(剂量范围为每日两次,20至60毫克)进行了研究。第二组16例患者遵循相同方案,但服用维拉帕米(每日三次,120至160毫克)。在两项研究期间,患者均接受了标准化生理测试,包括倾斜试验、等长握力试验和动态自行车运动试验。在研究的大部分24小时内,维拉帕米和硝苯地平均使血压降低。硝苯地平不影响心率,而维拉帕米使心率降低约10次/分钟。硝苯地平和维拉帕米均未诱发体位性低血压,并且对动态和等长运动的绝对反应降低。这些结果表明慢通道抑制剂在原发性高血压治疗中的疗效。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验